Levels of C-terminal propeptide of type I procollagen and oxyproline in patients with systemic lupus erythematosus: The relationship between the course of the disease and the structural and functional state of bone tissue

S V. Shevchuk; L. P. Denyschych; L. I. Marynych

doi:10.15421/021718

S V. Shevchuk National Pirogov Memorial Medical University
L. P. Denyschych National Pirogov Memorial Medical University
L. I. Marynych National Pirogov Memorial Medical University

Keywords: osteoporosis, bone turnover, bone mineral density

Abstract

The high prevalence of osteoporosis in patients with systemic lupus erythematosus (SLE) makes it necessary to study the abnormalities in bone metabolism, its relationship with reduced bone mineral density (BMD) and the impact of the disease on it. The aim of this study was to determine serum levels of C-terminal propeptide of type I procollagen (PICP) and oxyproline in patients with SLE, their comparison with the structural and functional state of the patients’ bone tissue and the course of the disease. We examined 58 female SLE patients. The mean age of the patients was 45.1 ± 1.0 years. The control group included 29 healthy individuals,corresponding in age and sex with the researched group. For every patient, data were recorded on age, body mass index (BMI), menstrual history, smoking, chronic SLE damage (SLICC/ACR DI) and disease activity score (SLEDAI), cumulative glucocorticoid dose, serum concentrations of interleukin-6 (IL-6) and C-reactive protein (CRP), bone formation marker (C-terminal propeptide of type I procollagen) and bone resorption marker (oxyproline). In all patients BMD was measured by DXA (Dual-energy X-ray absorptiometry) at two sites. To determine vertebral compression fractures, female SLE patients were examined with an x-ray of the thoracic and lumbar spine. We established that bone turnover markers showed a significant difference between the SLE patients and the control group, with lower levels of PICP and higher levels of oxyproline in the SLE patients. Alterations of bone metabolism were associated with the severity of the disease, active inflammation (high levels of CRP and IL-6), the age of the patients, and the high cumulative glucocorticoid dose but no correlation was found with disease duration, BMI and smoking. Patients with osteopenia, osteoporosis and fractures were significantly more frequently found among patients with reduced bone formation and increased bone resorption rate. Thus, our findings showed that female SLE patients have alterations of bone metabolism in the form of increasing serum oxyproline and reducing serum C-terminal propeptide of type I procollagen, the correction of which would slow the progression of adverse structural and functional changes in the bone tissue.

References

Ajeganova, S., Gustafsson, T., Jogestrand, T., Frostegard, J., & Hafström, I. (2015). Bone mineral density and carotid atherosclerosis in systemic lupus erythematosus: A controlled cross-sectional study. Arthritis Research and Therapy, 17, 84.

Amarasekara, D. S., Yu, J., & Rho, J. (2015). Bone loss triggered by the cytokine network in inflammatory autoimmune diseases. Journal of Immunology Research, 2015, 832127.

Baker-LePain, J. C., Nakamura, M. C., Shepherd, J., & von Scheven, E. (2011). Assessment of bone remodelling in childhood-onset systemic lupus erythematosus. Rheumatology (Oxford), 50(3), 611–619.

Becker, A., Fischer, R., Scherbaum, W. A., & Schneider, M. (2001). Osteoporosis screening in systemic lupus erythematosus: Impact of disease duration and organ damage. Lupus, 10(11), 809–814.

Bogaczewicz, J., Karczmarewicz, E., Pludowski, P., Zabek, J., Kowalski, J., Lukaszkiewicz, J., & Wozniacka, A. (2015). Feasibility of measurement of bone turnover markers in female patients with systemic lupus erythematosus. Revista Brasiliera de Reumatologia, 55(2), 133–139.

Bombardier, C., Gladman, D. D., Urowitz, M. B., Caron, D., & Chang, C. H. (1992). Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis and Rheumatology, 35(6), 630–640.

Borba, V. Z., Vieira, J. G., Kasamatsu, T., Radominski, S. C., Sato, E. I., & Lazaretti-Castro, M. (2009). Vitamin D deficiency in patients with active systemic lupus erythematosus. Osteoporosis International, 20(3), 427–433.

Bruyere, O., Collette, J., Delmas, P., Rouillon, A., Roux, C., Seidel, L., Richy, F., & Reginster, J. Y. (2003). Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal women. Maturitas, 44(4), 259–265.

Bultink, I. E. (2012). Osteoporosis and fractures in systemic lupus erythematosus. Arthritis Care and Research (Hoboken), 64(1), 2–8.

Bultink, I. E., & Lems, W. F. (2016). Lupus and fractures. Current Opinion in Rheumatology, 28(4), 426–432.

Canalis, E., Mazziotti, G., Giustina, A., & Bilezikian, J. P. (2007). Glucocorticoid-induced osteoporosis: Pathophysiology and therapy. Osteoporosis Interna-tional, 18(10), 1319–1328.

Carli, L., Tani, C., Spera, V., Vagelli, R., Vagnani, S., Mazzantini, M., Di Munno, O., & Mosca, M. (2016). Risk factors for osteoporosis and fragility fractures in patients with systemic lupus erythematosus. Lupus Science and Medicine, 3(1), e000098.

Chapurlat, R. D., Garnero, P., Sornay-Rendu, E., Arlot, M. E., Claustrat, B., & Delmas, P. D. (2000). Longitudinal study of bone loss in pre- and perimenopausal women: Evidence for bone loss in perimenopausal women. Osteoporosis International, 11(6), 493–498.

Cramarossa, G., Urowitz, M. B., Su, J., Gladman, D., & Touma, Z. (2016). Prevalence and associated factors of low bone mass in adults with systemic lupus erythematosus. Lupus, 2016.

Dovio, A., Perazzolo, L., Osella, G., Ventura, M., Termine, A., Milano, E., Bertolotto, A., & Angeli, A. (2004). Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. Journal of Clinical Endocrinology and Metabolism, 89(10), 4923–4938.

Garnero, P., Sornay-Rendu, E., Claustrat, B., & Delmas, P. D. (2000). Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study. Journal of Bone and Mineral Research, 15(8), 1526–1536.

Garnero, P., Sornay-Rendu, E., Duboeuf, F., & Delmas, P. D. (1999). Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: The OFELY study. Journal of Bone and Mineral Research, 14(9), 1614–1621.

Gladman, D., Ginzler, E. Goldsmith, C., Fortin, P., Liang, M., Urowitz, M., Bacon, P., Bombardieri, S., Hanly, J., Hay, E., Isenberg, D., Jones, J., Kalunian, K., Maddison, P., Nived, O., Petri, M., Richter, M., Sanchez-Guerrero, J., Snaith, M., Sturfelt, G., Symmons, D., & Zoma, A. (1996). The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis and Rheumatology, 39(3), 363–369.

Guo, Q., Fan, P., Luo, J., Wu, S., Sun, H., He, L., & Zhou, B. (2016). Assessment of bone mineral density and bone metabolism in young male adults recently diagnosed with systemic lupus erythematosus in China. Lupus, 26(3).

Handono, K., Sari, T. L., & Adam, A. A. (2014). Homocysteine, folic acid, vitamin B6, vitamin B12, and biochemical parameters of bone metabolism in female patients with systemic lupus erythematosus. Journal of Clinical and Cellular Immunology, 5(3), 217.

Hansen, M., Halberg, P., Kollerup, G., Pedersen-Zbinden, B., Hørslev-Petersen, K., Hyldstrup, L., & Lorenzen, I. (1998). Bone metabolism in patients with systemic lupus erythematosus. Effect of disease activity and glucocorticoid treatment. Scandinavian Journal of Rheumatology, 27(3), 197–206.

Hochberg, M. C. (1997). Updating the american college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis and Rheumatology, 40(9), 1725–1734.

Iki, M., Morita, A., Ikeda, Y., Sato, Y., Akiba, T., Matsumoto, T., Nishino, H., Kagamimori, S., Kagawa, Y., Yoneshima, H., & JPOS Study Group (2006). Biochemical markers of bone turnover predict bone loss in perimenopausal women but not in postmenopausal women – the Japanese Population – based Osteoporosis (JPOS) Cohort Study. Osteoporosis International, 17(7), 1086–1095.

Korczowska, I., Olewicz-Gawlik, A., Hrycaj, P., & Lacki, J. (2003). The effect of long-term glucocorticoids on bone metabolism in systemic lupus erythematosus patients: The prevalence of its anti-inflammatory action upon bone resorption. Yale Journal of Biology and Medicine, 76(2), 45–54.

Li, E. K., Tam, L. S., Griffith, J. F., Zhu, T. Y., Li, T. K., Li, M., Wong, K. C., Chan, M., Lam, C. W., Chu, F. S., Wong, K. K., Leung, P. C., & Kwok, A. (2009). High prevalence of asymptomatic vertebral fractures in Chinese women with systemic lupus erythematosus. Journal of Rheumatology, 36(8), 1646–1652.

Melton, L. J. 3rd., Crowson, C. S., O’Fallon, W. M., Wahner, H. W., & Riggs, B. L. (2003). Relative contribution of bone density, bone turnover, and clinical risk factors to long-term fracture prediction. Journal of Bone and Mineral Research, 18(2), 312–318.

Mendoza-Pinto, C., García-Carrasco, M., Sandoval-Cruz, H., Muñoz-Guarneros, M., Escárcega, R. O., Jiménez-Hernández, M., Munguía-Realpozo, P., Sandoval-Cruz, M., Delezé-Hinojosa, M., López-Colombo, A., & Cervera, R. (2009). Risk factors of vertebral fractures in women with systemic lupus erythematosus. Clinical Rheumatology, 28(5), 579–585.

Redlich, K., Ziegler, S., Kiener, H. P., Spitzauer, S., Stohlawetz, P., Bernecker, P., Kainberger, F., Grampp, S., Kudlacek, S., Woloszczuk, W., Smolen, J. S., & Pietschmann, P. (2000). Bone mineral density and biochemical parameters of bone metabolism in female patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 59(4), 308–310.

Rees, F., Doherty, M., Grainge, M., Lanyon, P., Davenport, G., & Zhang, W. (2016). Burden of comorbidity in systemic lupus erythematosus in the UK. Arthritis Care and Research (Hoboken), 68(6), 819–827.

Ross, P. D., Kress, B. C., Parson, R. E., Wasnich, R. D., Armour, K. A., & Mizrahi, I. A. (2000). Serum bone alkaline phosphatase and calcaneus bone density predict fractures: A prospective study. Osteoporosis Interbational, 11(1), 76–82.

Stepan, J. J. (2000). Prediction of bone loss in premenopausal women. Osteoporosis International, 11(3), 545–554.

Sun, Y. N., Feng, X. Y., He, L., Zeng, L. X., Hao, Z. M., Lv, X. H., & Pu, D. (2015). Prevalence and possible risk factors of low bone mineral density in untreated female patients with systemic lupus erythematosus. Biomed Research International, 2015, 510–514.

Tang, Y., Xie, H., Chen, J., Geng, L., Chen, H., Li, X., Hou, Y., Lu, L., Shi, S., Zeng, X., & Sun, L. (2013). Activated NF-κB in bone marrow mesenchymal stem cells from systemic lupus erythematosus patients inhibits osteogenic differentiation through downregulating Smad signaling. Stem Cells and Development, 22(4), 668–678.

Teichmann, J., Lange, U, Stracke, H., Federlin, K., & Bretzel, R. G. (1999). Bone metabolism and bone mineral density of systemic lupus erythematosus at the time of diagnosis. Rheumatology International, 18(4), 137–140.

Wang, X., Yan, S., Liu, C., Xu, Y., Wan, L., Wang, Y., Gao, W., Meng, S., Liu, Y., Liu, R., & Xu, D. (2016). Fracture risk and bone mineral density levels in patients with systemic lupus erythematosus: A systematic review and meta-analysis. Osteoporosis International, 27(4), 1413–1423.